Reversing Diabetic Peripheral Neuropathy Through Exercise
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- New York University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be between the ages of 40 and 70
- Clinical diagnosis of Type 2 diabetes
- Clinical diagnosis of DPN
- Have a BMI less than 40 kg/m2 (due to magnet bore restrictions)
- Able to walk unassisted
Exclusion Criteria:
- Serious cardiac pathology or musculoskeletal problems that would limit exercise ability
- MNSI score < 1
- Current open wound or history of plantar ulcer for the last 3 months
- Partial foot amputations
- Inability to ambulate without assistive device
- Stroke or other central nervous system pathology
- Stage 2 hypertension (resting blood pressure >160 systolic or >100 diastolic)
- Contraindications to 3T whole body MRI scanners (e.g., pacemaker, cerebral aneurysm clip, cochlear implant, presence of shrapnel in strategic locations, metal in the eye, claustrophobia, or other problems).
- Subjects with alcoholism, chronic drug use, chronic gastrointestinal disease, or renal or hepatic impairment
- Pregnant women and children
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Patients with Type 2 Diabetes and Clinical Symptoms of DPN
Patients will be individually prescribed to a 10-week exercise program with both aerobic and resistance components.
Prior to beginning the intervention, patients will participate in a maximal graded exercise test (VO2R) using a cycle ergometer with a metabolic cart and integrated ECG.
|
The exercise program will combine moderate intensity aerobic exercise with lower-extremity specific resistance training.
A moderate level of intensity will be calculated based on results from a maximal graded exercise test (VO2R) conducted prior to the intervention.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Mass Index (BMI)
Time Frame: Baseline
|
The BMI calculation divides an adult's weight in kilograms by their height in meters squared.
|
Baseline
|
|
Change From Baseline in Body Mass Index (BMI)
Time Frame: Week 10
|
The BMI calculation divides an adult's weight in kilograms by their height in meters squared.
|
Week 10
|
|
Glycosylated Hemoglobin (HbA1c)
Time Frame: Baseline
|
The glycosylated hemoglobin test shows what a person's average blood glucose level was for the 2 to 3 months before the test.
Measured via patient blood samples.
|
Baseline
|
|
Glycosylated Hemoglobin (HbA1c)
Time Frame: Week 10
|
The glycosylated hemoglobin test shows what a person's average blood glucose level was for the 2 to 3 months before the test.
Measured via patient blood samples.
|
Week 10
|
|
C-Reactive Protein Levels
Time Frame: Baseline
|
Measured via patient blood samples.
|
Baseline
|
|
C-Reactive Protein Levels
Time Frame: Week 10
|
Measured via patient blood samples.
|
Week 10
|
|
Michigan Neuropathy Screening Instrument (MNSI) Symptom Questionnaire
Time Frame: Baseline
|
15-question assessment of symptoms.
Responses of "yes" to items 1-3, 5-6, 8-9, 11-12, 14-15 are each counted as one point.
A "no" response on items 7 and 13 counts as 1 point.
Item 4 is a measure of impaired circulation and item 10 is a measure of general asthenia; neither are included in scoring.
The total score ranges from 0-13; lower scores indicate less prevalent symptoms; a decrease in scores indicates symptoms decreased during the observational period.
|
Baseline
|
|
Michigan Neuropathy Screening Instrument (MNSI) Symptom Questionnaire
Time Frame: Week 10
|
15-question assessment of symptoms.
Responses of "yes" to items 1-3, 5-6, 8-9, 11-12, 14-15 are each counted as one point.
A "no" response on items 7 and 13 counts as 1 point.
Item 4 is a measure of impaired circulation and item 10 is a measure of general asthenia; neither are included in scoring.
The total score ranges from 0-13; lower scores indicate less prevalent symptoms; a decrease in scores indicates symptoms decreased during the observational period.
|
Week 10
|
|
MNSI Physical Exam Score
Time Frame: Baseline
|
Completed by physician.
Assessment of abnormalities in the appearance of the feet, vibration sense, reflexes, and monofilament sensation.
The total score ranges from 0-10; lower scores indicate greater physical health; a decrease in scores indicates physical health increased during the observational period.
|
Baseline
|
|
MNSI Physical Exam Score
Time Frame: Week 10
|
Completed by physician.
Assessment of abnormalities in the appearance of the feet, vibration sense, reflexes, and monofilament sensation.
The total score ranges from 0-10; lower scores indicate greater physical health; a decrease in scores indicates physical health increased during the observational period.
|
Week 10
|
|
Calf Muscle Performance
Time Frame: Baseline
|
Performance will be quantified as peak ankle plantarflexion torque at 60 degrees/sec.
|
Baseline
|
|
Calf Muscle Performance
Time Frame: Week 10
|
Performance will be quantified as peak ankle plantarflexion torque at 60 degrees/sec.
|
Week 10
|
|
Physical Performance Test (PP) Score
Time Frame: Baseline
|
9-item assessment of Physical Performance.
The total score ranges from 0 to 36; higher scores indicate greater levels of physical performance.
|
Baseline
|
|
Physical Performance Test (PP) Score
Time Frame: Week 10
|
9-item assessment of Physical Performance.
The total score ranges from 0 to 36; higher scores indicate greater levels of physical performance.
|
Week 10
|
|
PCr Resynthesis Rate in the Gastrocnemius Muscle Groups
Time Frame: Baseline
|
Measured using multinuclear-MRI following a 90-second plantar flexion exercise during which resistance is applied at approximately 40% of the individual's maximum voluntary contraction.
The value reported in the data table represents the average flexion across both calf muscles.
|
Baseline
|
|
PCr Resynthesis Rate in the Gastrocnemius Muscle Groups
Time Frame: Week 10
|
Measured using multinuclear-MRI following a 90-second plantar flexion exercise during which resistance is applied at approximately 40% of the individual's maximum voluntary contraction.
The value reported in the data table represents the average flexion across both calf muscles.
|
Week 10
|
|
Intramuscular Adipose Tissue (IMAT) Levels in the Gastrocnemius Muscle Groups
Time Frame: Baseline
|
Measured using IDEAL-MRI.
IMAT levels are quantified as a percentage of total tissue in the gastrocnemius muscle groups of both calf muscles combined.
|
Baseline
|
|
Intramuscular Adipose Tissue (IMAT) Levels in the Gastrocnemius Muscle Groups
Time Frame: Week 10
|
Measured using IDEAL-MRI.
IMAT levels are quantified as a percentage of total tissue in the gastrocnemius muscle groups of both calf muscles combined.
|
Week 10
|
|
IMAT Levels in the Soleus Muscle Groups
Time Frame: Baseline
|
Measured using IDEAL-MRI.
IMAT levels are quantified as a percentage of total tissue in the soleus muscle groups of both calf muscles combined.
|
Baseline
|
|
IMAT Levels in the Soleus Muscle Groups
Time Frame: Week 10
|
Measured using IDEAL-MRI.
IMAT levels are quantified as a percentage of total tissue in the soleus muscle groups of both calf muscles combined.
|
Week 10
|
|
Fractional Anisotropy (FA) in the Tibial Nerve
Time Frame: Baseline
|
FA is a scalar value between zero and one that describes the degree of anisotropy of a diffusion process.
A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions.
A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions.
Measured using Diffusion Tensor Imaging (DTI).
|
Baseline
|
|
Fractional Anisotropy (FA) in the Tibial Nerve
Time Frame: Week 10
|
FA is a scalar value between zero and one that describes the degree of anisotropy of a diffusion process.
A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions.
A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions.
Measured using Diffusion Tensor Imaging (DTI).
|
Week 10
|
|
Apparent Diffusion Coefficient (ADC) in the Tibial Nerve
Time Frame: Baseline
|
ADC is a measure of the magnitude of diffusion (of water molecules) within tissue.
Measured using DTI.
|
Baseline
|
|
Apparent Diffusion Coefficient (ADC) in the Tibial Nerve
Time Frame: Week 10
|
ADC is a measure of the magnitude of diffusion (of water molecules) within tissue.
Measured using DTI.
|
Week 10
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ryan Brown, PhD, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 18-00527
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.